Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
8 Y9 e. H0 T# U( `8 \& l9 I! V! sNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 x2 N1 g% {2 s7 _& Y. Q
+ Author Affiliations
7 I9 x* p b7 u- k
0 k+ r A4 e4 L1 v1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2 `' f' ~ Q. Y/ ~/ u# ]2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 1 o2 r0 T4 Q. m# f" W1 t1 h4 k
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
4 B1 P' y1 f G' C0 o9 V4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
2 p2 d6 ]9 S2 E1 y5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 3 d: G, G. u" s5 c, `% O
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 2 C0 o" f+ {9 v4 f) F; c
7Kinki University School of Medicine, Osaka 589-8511, Japan / d/ o+ ]; O3 w* ~, i
8Izumi Municipal Hospital, Osaka 594-0071, Japan 3 b( N9 G, u+ \
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
# }" J, Y* p8 J2 xCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
/ b+ z' U+ \) FAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
) ] `4 f# ]$ w
, L6 i* P5 n! }! m# ~ |